v3.8.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Revenue:        
Tc99m tilmanocept sales revenue $ 17,601 $ 30,800
Tc99m tilmanocept license revenue 1,295,625 100,000 1,795,625
Grant and other revenue 223,669 510,974 1,315,298 2,113,420
Total revenue 223,669 1,824,200 1,415,298 3,939,845
Cost of goods sold 2,889 5,185
Gross profit 223,669 1,821,311 1,415,298 3,934,660
Operating expenses:        
Research and development 874,547 919,441 2,765,695 5,010,923
Selling, general and administrative 1,734,707 1,811,680 9,006,725 5,832,623
Total operating expenses 2,609,254 2,731,121 11,772,420 10,843,546
Loss from operations [1] (2,385,585) (909,810) (10,357,122) (6,908,886)
Other income (expense):        
Interest income (expense), net 76,050 159 144,811 (2,076)
Equity in loss of R-NAV, LLC (15,159)
Loss on disposal of investment in R-NAV, LLC (39,732)
Change in fair value of financial instruments (839,298) 153,357 1,755,989
Loss on extinguishment of debt (1,314,102)
Other, net (6,979) (12,498) (45,256) (49,916)
Total other income (expense), net 69,071 (851,637) (1,061,190) 1,649,106
Loss before income taxes (2,316,514) (1,761,447) (11,418,312) (5,259,780)
Benefit from income taxes 775,750 0 3,861,156
Loss from continuing operations (1,540,764) (1,761,447) (7,557,156) (5,259,780)
Discontinued operations, net of tax effect:        
Income (loss) from discontinued operations 5,399 1,701,911 (332,838) (5,167,312)
Gain on sale 145,877 86,894,000
Net income (loss) (1,389,488) (59,536) 79,004,006 (10,427,092)
Less loss attributable to noncontrolling interest (23) (159) (192) (516)
Net income (loss) attributable to common stockholders $ (1,389,465) $ (59,377) $ 79,004,198 $ (10,426,576)
Income (loss) per common share (basic):        
Continuing operations (in dollars per share) $ (0.01) $ (0.01) $ (0.05) $ (0.03)
Discontinued operations (in dollars per share) 0.01 0.54 (0.04)
Attributable to common stockholders (in dollars per share) $ (0.01) $ 0.49 $ (0.07)
Weighted average shares outstanding (basic) (in shares) 162,006,646 155,481,278 161,437,276 155,390,911
Income (loss) per common share (diluted):        
Continuing operations (in dollars per share) $ (0.01) $ (0.01) $ (0.05) $ (0.03)
Discontinued operations (in dollars per share) 0.01 0.52 (0.04)
Attributable to common stockholders (in dollars per share) $ (0.01) $ 0.47 $ (0.07)
Weighted average shares outstanding (diluted) (in shares) 162,006,646 155,481,278 165,914,473 155,390,911
[1] Income (loss) from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.

Source